email article
The addition of an immunomodulating agent to pegloticase (Krystexxa) among patients with uncontrolled gout significantly improved response rates, a systematic literature review found.
In a cohort of patients whose gout had been refractory to conventional therapy, co-treatment with pegloticase plus an immunomodulator was associated with an overall response rate of 82.9%, reported Robert T. Keenan, MD, of Duke University in Durham, North Carolina, and colleagues.
That rate was "markedly higher" than the 42% that had been observed for pegloticase monotherapy in clinical trials, Keenan and co-authors noted in their study online in
Pegloticase is approved for patients with chronic gout who have inadequate serum urate control with xanthine oxidase inhibitors at the highest medically appropriate dose or in whom these drugs are contraindicated.